>

MEETINGS / EVENTS

RSS

May 05 - 07 2014, 12:00 AM - 12:00 AM

2014 ASA Legislative Conference

>

FDA MEDWATCH ALERTS

April 18, 2014

Propofol Injectable Emulsion, USP by Hospira: Recall - Visible Particulates

Summary:

Propofol Injectable Emulsion USP by Hospira Recall Visible Particulates

April 18, 2014

FDA MedWatch - ARKON Anesthesia Delivery System with Version 2.0 Software by Spacelabs Healthcare: Class I Recall

Summary:

FDA MedWatch Class I Recall 4 18 14

March 28, 2014

FDA Update on the Shortage of Normal Saline

Summary:

FDA Update on the Shortage of Normal Saline

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-14CE

... Read more »

Single Copies, Member Price: $360

FDA Alerts and Recalls

AUDIENCE: Surgery, Anesthesia, Neurology, Healthcare Professionals

ISSUE: FDA has observed fungal contamination by direct microscopic examination of foreign matter taken from a sealed vial of methylprednisolone acetate collected from New England Compounding Center (NECC). FDA is in the process of conducting additional microbial testing to confirm the exact species of the fungus.

Investigation into the exact source of the outbreak is still ongoing, but the outbreak is associated with a potentially contaminated medication. That product is preservative-free methylprednisolone acetate (80mg/ml), an injectable steroid produced and distributed by New England Compounding Center (NECC) in Framingham, Massachusetts. CDC’s interim data show that all infected patients received injection with this product.

BACKGROUND: FDA was been working closely with CDC, several state health departments, and the Massachusetts Board of Pharmacy to investigate the scope and cause of the outbreak of fungal meningitis. FDA inspectors in the New England District Office, in cooperation with the Massachusetts Board of Registration in Pharmacy have been conducting an inspection of the New England Compounding Center. The firm voluntarily ceased all operations and surrendered its license to the Massachusetts Board of Registration in Pharmacy on October 3, 2012.

RECOMMENDATION: Out of an abundance of caution, FDA is taking the additional step of recommending that health care professionals and consumers not use any product that was produced by NECC at this time. In addition, FDA requests that health care professionals retain and secure all remaining products purchased from NECC until FDA provides further instructions regarding the disposition of these products.

Although the investigation into the source of the outbreak is still ongoing, if you have purchased a product from NECC, FDA is advising not to use it at this time. This includes all products compounded and distributed at NECC; not just the ones that have been recalled. Please see the CDC website for additional information.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

Complete and submit the report Online: www.fda.gov/MedWatch/report.htm

 

Download form

or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Read the MedWatch safety alert, incliding links to the FDA statement, Q&As, and list of recalled products, at:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm322849.htm


You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm

Follow MedWatch on Twitter

Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@govdelivery.com.

This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

Alerts By Date

1–20 of 130 results
Show:

Friday, April 18, 2014

Propofol Injectable Emulsion, USP by Hospira: Recall - Visible Particulates

Propofol Injectable Emulsion USP by Hospira Recall Visible Particulates

view details »

Friday, March 28, 2014

FDA Update on the Shortage of Normal Saline

FDA Update on the Shortage of Normal Saline

view details »

Tuesday, March 18, 2014

McKesson Technologies Anesthesia Care: Recall - Patient Case Data May Not Match Patient Data

McKesson Technologies Anesthesia Care Recall Patient Case Data May Not Match Patient Data

view details »

Monday, February 10, 2014

Calcium gluconate 10 percent Injections by Rx Formulations: Recall - Microbial Contamination

Calcium gluconate 10 percent Injections by Rx Formulations Recall Microbial Contamination

view details »

Monday, January 13, 2014

FDA Removes Unapproved Prescription Drug Products Containing Codeine and Dihydrocodeine from the Market

FDA Removes Unapproved Prescription Drug Products Containing Codeine and Dihydrocodeine

view details »

Tuesday, November 26, 2013

Hospira GemStar Infusion System: Class I Recall - Pressure Sensor Calibration Drift

Hospira GemStar Infusion System Class I Recall Pressure Sensor Calibration Drift

view details »

Monday, November 18, 2013

Nature's Pharmacy and Compounding Center Sterile Compounded Products: Recall - Lack of Sterility Assurance

Natures Pharmacy and Compounding Center Sterile Compounded Products Recall

view details »

Friday, October 25, 2013

MedStream Programmable Infusion Pump and Refill Kits by Codman and Shurtleff: Class 1 Recall - Drug Over Infusion

MedStream Programmable Infusion Pump and Refill Kits by Codman and Shurtleff

view details »